Page 38 - APPENDICES for Peter Yesawich
P. 38

^ƒ„…B:†† IAB@…;PQ R R QSTUVWXYZ[\]  5^W_`Wasc efT  gh iV jT k hRgU  lp  5^au
    9:;P
             	
 	 
         
     	       56 7   8 FGH IJKLMNMOKNLR U 5^W_`W qX3Zrbstcubarsubcd ^ `qZ_v\^auuwceex Q S  y  R   kV ziQS  Q h QlQ   hRgU { yR  Sg   liQQ   hRgU { yR  Sg   liQ

      ]^n5\]  5`o~RgU h hg QS  6
     3  	
   W €	 † >:?@A=B: C DE=< FGH IJm R U W_`W qX3Zrtssctex Q S  y  R   kV ziQS  Q h QlQ   hRgU { yR  Sg   liQ
                 !"#$%& '( ") *+ ,-.& /01%23	    3  	
  34 <= >:?@A=B: C DE=<Q R R QSTUVWXYZ[\]  5^W_`WabcdefT  gh iV jT k hRgU  lm p  a| S }lRh R y  R   kV ziQS  Q h Ql     ‚     7   8KKLNMM‡NL

      ]^n5\]  5`o




                                                                  These are the lowest-cost stand-alone drug
                                                                  plans for your Rx drugs.












                                                             This plan's costs are
                                                             summarized in your
                                                             evaluation. Its
                                                             benefit summary is
                                                             in Appendix C2.
   33   34   35   36   37   38   39   40   41   42   43